What are the latest treatment options for advanced melanoma

MelanomaOctober 15, 2025Navis AI

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

I'll help explain the current treatment options for advanced melanoma, according to the latest guidelines from trusted medical organizations.

According to the 2023 NCCN Guidelines for Cutaneous Melanoma, the main first-line treatment options for advanced melanoma include:

  1. Immunotherapy:
  • Anti-PD-1 therapy (pembrolizumab or nivolumab)
  • Combination of nivolumab plus ipilimumab
  • These treatments help your immune system fight the cancer cells
  1. Targeted Therapy: The American Society of Clinical Oncology (ASCO) guidelines indicate that for patients with BRAF-mutated melanoma (approximately 40-50% of cases), the following combinations are recommended:
  • BRAF inhibitor + MEK inhibitor combinations: • Dabrafenib + Trametinib • Vemurafenib + Cobimetinib • Encorafenib + Binimetinib

The National Cancer Institute (NCI) also highlights newer treatment approaches, including:

  • Clinical trials of novel combinations
  • Tumor-infiltrating lymphocyte (TIL) therapy
  • Updated combinations of existing immunotherapies

Important notes:

  • Treatment selection depends on several factors, including: • BRAF mutation status • Overall health status • Rate of disease progression • Previous treatments received

Always consult with your healthcare team to determine the best treatment plan for your specific situation, as they can take into account your individual case details and preferences.

Would you like me to explain any of these treatment options in more detail?

This is general information.

Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.

Get guidance specific to your case

This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history: